Zápis Sample Clauses

Zápis. Prior to the initiation of enrollment, ▇▇▇▇▇▇▇ will have the right to publicly register protocol summaries and site contact details from company sponsored trials of both investigational medicinal products and marketed medicinal products that meet at least one of the following criteria: (i) required to be registered by Janssen or one of its affiliates pursuant to and in accordance with applicable laws and regulations; (ii) required by the ICMJE for studies intended to be published in the international peer-reviewed literature (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇); or (iii) from company sponsored trials of both investigational and marketed medicines and products that are adequately-designed and well-controlled, whether or not required by (i) or (ii) of this section above. In accordance with the legislation of the Czech Republic, the Clinical Trial description shall be published on the internet site of State Institute for Drug Control ▇▇▇.▇▇▇▇.▇▇ and will also be available on the website ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇/index.html and ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇, as required by the legislation of the EU and the USA. In addition, equivalent websites and websites of Janssen and its affiliates may be used for registration purposes. Společnost ▇▇▇▇▇▇▇ má právo před zahájením zápisu veřejně zapsat shrnutí protokolu a kontaktní údaje pracoviště z hodnocení zadaných společností jak u hodnocených přípravků, tak u registrovaných léčiv, která splňují nejméně jedno z následujících kritérií: (i) společnost Janssen nebo jedna z jejích přidružených společností je povinna je registrovat podle platných zákonů a předpisů a v souladu s nimi; (ii) vyžaduje to ICMJE pro studie, které mají být publikovány v recenzované mezinárodní literatuře (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇); nebo (iii) z klinických studií hodnocených i registrovaných léčiv a přípravků zadaných společností, které byly odpovídajícím způsobem navrženy a dobře řízeny bez ohledu na to, zda to vyžaduje bod (i) nebo (ii) výše v tomto bodě, či nikoli. Popis klinického hodnocení bude v souladu s legislativou České republiky zveřejněn na internetových stránkách Státního ústavu pro kontrolu léčiv ▇▇▇.▇▇▇▇.▇▇ a bude dostupný také na ▇▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇/index.html a ▇▇▇.▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇, jak požaduje legislativa EU a USA. Kromě toho lze pro registrační účely použít ekvivalentní webové stránky a oficiální webové stránky společnosti Janssen nebo jejích přidružených společností. Any person accessing a clinical trial listing for a cli...
Zápis. Prior to the initiation of enrollment, ▇▇▇▇▇▇▇ will have the right to publicly register protocol summaries and site contact details from company sponsored trials of both investigational medicinal products and marketed medicinal products that meet at least one of the following criteria: (i) Společnost Janssen má právo před zahájením zápisu veřejně zapsat shrnutí protokolu a kontaktní údaje pracoviště z hodnocení zadaných společností jak u hodnocených přípravků, tak u registrovaných léčiv, která splňují nejméně jedno z následujících kritérií: (i)
Zápis. Prior to the initiation of enrollment, ▇▇▇▇▇▇▇ will have the right to publicly register protocol summaries and site contact details from company sponsored trials of both investigational medicinal products and marketed medicinal products that meet at least one of the following criteria:
Zápis. Prior to the initiation of enrollment, Janssen will have the right to publicly register protocol summaries and site contact details from company Společnost Janssen má právo před zahájením zápisu veřejně zapsat shrnutí protokolu a kontaktní údaje pracoviště z hodnocení
Zápis. Prior to the initiation of enrollment, Sponsor will have the right to publicly register protocol summaries and site contact details from company sponsored trials of both investigational medicinal products and marketed medicinal products that meet at least one of the following criteria: (i) required to be registered by Sponsor pursuant to and in accordance with applicable Zadavatel má právo před zahájením zápisu veřejně zapsat shrnutí protokolu a kontaktní údaje pracoviště z hodnocení zadaných společností jak u hodnocených přípravků, tak u léčiv, která splňují nejméně jedno z následujících kritérií: (i) zadavatel je povinen je registrovat podle platných zákonů a předpisů a v souladu s nimi; (ii) ICMJE pro studie vyžadují jejich zveřejnění v mezinárodní literatuře

Related to Zápis

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time. (b) The Supplier shall not change any process, material, component, packaging or manufacturing location without the Purchaser’s express prior written approval.

  • TECHNICAL EVALUATION (a) Detailed technical evaluation shall be carried out by Purchase Committee pursuant to conditions in the tender document to determine the substantial responsiveness of each tender. For this clause, the substantially responsive bid is one that conforms to all the eligibility and terms and condition of the tender without any material deviation. The Institute’s determination of bid’s responsiveness is to be based on the contents of the bid itself without recourse to extrinsic evidence. The Institute shall evaluate the technical bids also to determine whether they are complete, whether required sureties have been furnished, whether the documents have been properly signed and whether the bids are in order. (b) The technical evaluation committee may call the responsive bidders for discussion or presentation to facilitate and assess their understanding of the scope of work and its execution. However, the committee shall have sole discretion to call for discussion / presentation. (c) Financial bids of only those bidders who qualify the technical criteria will be opened provided all other requirements are fulfilled. (d) AIIMS Jodhpur shall have right to accept or reject any or all tenders without assigning any reasons thereof.

  • Evaluation Software If the Software is an evaluation version or is provided to You for evaluation purposes, then, unless otherwise approved in writing by an authorized representative of Licensor, Your license to use the Software is limited solely for internal evaluation purposes in non-production use and in accordance with the terms of the evaluation offering under which You received the Software, and expires 90 days from installation (or such other period as may be indicated within the Software). Upon expiration of the evaluation period, You must discontinue use of the Software, return to an original state any actions performed by the Software, and delete the Software entirely from Your system and You may not download the Software again unless approved in writing by an authorized representative of Licensor. The Software may contain an automatic disabling mechanism that prevents its use after a certain period of time. RESTRICTIONS

  • Labelling A label shall be permanently affixed on each container with at least the following information: name of the manufacturer, serial number, date of manufacture, MFP, NWP, type of fuel (e.g. "

  • Software Development Software designs, prototypes, and all documentation for the final designs developed under this agreement must be made fully transferable upon direction of NSF. NSF may make the software design, prototype, and documentation for the final design available to competitors for review during any anticipated re-competition of the project.